These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 23494482)

  • 1. Biologic agents in experimental autoimmune uveitis.
    Giuliari GP; Sadaka A; Hinkle DM
    Int Ophthalmol; 2014 Feb; 34(1):145-56. PubMed ID: 23494482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutting-edge issues in autoimmune uveitis.
    Levy RA; de Andrade FA; Foeldvari I
    Clin Rev Allergy Immunol; 2011 Oct; 41(2):214-23. PubMed ID: 21913066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The prospects of the biotherapy for refractory uveitis].
    Zheng YZ
    Zhonghua Yan Ke Za Zhi; 2016 Jul; 52(7):551-6. PubMed ID: 27531117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating intraocular inflammatory disease in the 21st century.
    Nussenblatt R
    Arch Ophthalmol; 2005 Jul; 123(7):1000-1. PubMed ID: 16009844
    [No Abstract]   [Full Text] [Related]  

  • 5. Infliximab in uveitis treatment.
    Rudometkin N; Mandava N; Deane K; Olson JL
    Arch Ophthalmol; 2006 Aug; 124(8):1211; author reply 1211-2. PubMed ID: 16908832
    [No Abstract]   [Full Text] [Related]  

  • 6. [Uveitis associated with juvenile idiopathic arthritis : Optimization of immunomodulatory therapy].
    Heiligenhaus A; Tappeiner C; Walscheid K; Heinz C
    Ophthalmologe; 2016 May; 113(5):391-7. PubMed ID: 27142035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis.
    Maleki A; Meese H; Sahawneh H; Foster CS
    Expert Rev Clin Immunol; 2016 Jul; 12(7):775-86. PubMed ID: 26972783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of posterior noninfectious uveitis : Current situation and future developments].
    Pleyer U; Pohlmann D; Stübiger N
    Ophthalmologe; 2016 May; 113(5):380-90. PubMed ID: 27165275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis.
    Demir T; Gödekmerdan A; Balbaba M; Türkçüoglu P; Ilhan F; Demir N
    Indian J Ophthalmol; 2006 Dec; 54(4):241-5. PubMed ID: 17090875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile.
    Neri P; Arapi I; Nicolai M; Pirani V; Saitta A; Luchetti MM; Giovannini A; Mariotti C
    Curr Drug Saf; 2016; 11(1):47-54. PubMed ID: 26463249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional immunosuppressive therapy in severe Behcet's Uveitis: the switch rate to the biological agents.
    Celiker H; Kazokoglu H; Direskeneli H
    BMC Ophthalmol; 2018 Oct; 18(1):261. PubMed ID: 30290779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the use of tumor necrosis factoralpha inhibitors in refractory uveitis.
    Sebastian RT; Harding SP; Bucknall RC; Pearce IA
    Arch Ophthalmol; 2006 Oct; 124(10):1505; author reply 1505-6. PubMed ID: 17030729
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of biologic agents in the management of uveitis.
    Trivedi A; Katelaris C
    Intern Med J; 2019 Nov; 49(11):1352-1363. PubMed ID: 30582273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New biologic drugs: anti-interleukin therapy.
    Tappeiner C; Möller B; Hennig M; Heiligenhaus A
    Dev Ophthalmol; 2012; 51():79-89. PubMed ID: 22517206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of interleukins and their inhibitors in the development of autoimmune uveitis.
    Kuryltsiv NB; Halei KM
    Wiad Lek; 2019; 72(4):716-722. PubMed ID: 31055563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials in noninfectious uveitis.
    Kim JS; Knickelbein JE; Nussenblatt RB; Sen HN
    Int Ophthalmol Clin; 2015; 55(3):79-110. PubMed ID: 26035763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of autoimmune uveitis.
    Whitcup SM; Nussenblatt RB
    Ann N Y Acad Sci; 1993 Nov; 696():307-18. PubMed ID: 8109836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.